Ipamorelin vs tesamorelin: one is an approved drug, the other is not

Tesamorelin is the stronger choice on evidence, and the comparison is lopsided enough that “better” is almost the wrong question. Tesamorelin is an FDA-approved prescription drug with a label, a fixed dose, two phase 3 trials and a known side-effect table. Ipamorelin, usually sold alongside CJC-1295 (see the CJC-1295 and ipamorelin guide), is approved for nothing, has no label, and was only ever given by vein in published studies. Products labeled “for research use only” are not legal to use on people.

The catch is that tesamorelin is approved for one narrow use, and that use is probably not yours. Its label says plainly that it “is not indicated for weight loss management as it has a weight neutral effect.” So the real comparison is between a drug with evidence for a condition most readers do not have, and a drug with no evidence at all.

Side by side

Mechanism

Growth hormone release from the pituitary is controlled by two main switches. One is the growth hormone-releasing hormone (GHRH) receptor. Tesamorelin binds it, as do sermorelin and CJC-1295; its label says it binds and stimulates human GHRH receptors “with similar potency as the endogenous GRF.” The other is the ghrelin receptor. Ipamorelin binds that one. In pigs, ipamorelin released growth hormone without raising ACTH or cortisol even at doses more than 200 times the effective dose, which set it apart from older peptides that act on the same receptor.

Both end in the same place: more growth hormone, and then more IGF-1, the hormone the liver makes in response. Neither has been shown to build muscle or improve sleep in a controlled trial.

FDA status

Tesamorelin is the only approved drug in this comparison. Its label limits it to one use, reducing excess abdominal fat in HIV-infected adults with lipodystrophy, and adds that it “is not indicated for weight loss management as it has a weight neutral effect.” Long-term cardiovascular safety “has not been established.” Use for anything else is off-label prescribing of an approved drug.

Ipamorelin has no approval for any use. FDA placed ipamorelin acetate in category 2 for 503A and 503B compounding on September 29, 2023. On October 29, 2024, the Pharmacy Compounding Advisory Committee reviewed it for growth hormone deficiency and postoperative ileus and voted against adding either form to the bulks list, citing a lack of information supporting safety and efficacy. FDA’s May 14, 2026 list shows it in no 503A category, and its safety-risk page still lists ipamorelin acetate in 503B category 2. There is no lawful route for a pharmacy to compound it under 503A.

Evidence

Tesamorelin. Two 26-week randomized, placebo-controlled phase 3 trials in adults with HIV-associated lipodystrophy used 2 mg daily. Visceral fat measured by CT scan fell by 27 and 21 cm² on average, versus a rise of 4 cm² and no change on placebo. In percentage terms that was 18% and 14% versus +2% and -2%. Extension phases followed patients to 52 weeks.

Ipamorelin. The published human data are a 1999 dose-ranging study in healthy men, which measured how fast it cleared (half-life about 2 hours) and showed a single growth hormone peak at about 40 minutes, and the Helsinn trials in bowel surgery patients. The first of those found no significant difference from placebo on key or secondary outcomes. The second, with 320 patients, finished in 2014 with no posted results. We found no published trial of ipamorelin injected under the skin.

Doses studied

Tesamorelin’s label sets the dose: Egrifta WR is 1.28 mg injected under the skin once daily, which the label says gives exposure comparable to the 2 mg dose of the original Egrifta used in the phase 3 trials. The label also states that Egrifta WR and the earlier Egrifta SV “are not substitutable.”

Ipamorelin has no labeled dose. The studies gave 0.03 mg/kg by intravenous infusion twice daily (about 2.1 mg per infusion for a 70 kg adult) or single 15-minute infusions of 4.21 to 140.45 nmol/kg, about 3 to 100 mcg/kg. The CJC-1295 and ipamorelin dosage page explains why daily under-the-skin protocols found online are not supported by those studies.

Side effects

Tesamorelin, from the label’s pooled 26-week data (543 on drug, 263 on placebo):

The label’s warnings section counts a broader set of injection site reactions over the first 26 weeks and puts those at 25% versus 14% on placebo. It also warns about raised IGF-1 (47% had IGF-1 more than 2 standard deviations above normal at 26 weeks), fluid retention and carpal tunnel symptoms, glucose intolerance (HbA1c of 6.5% or higher in 5% versus 1% on placebo), and hypersensitivity reactions in 4%. It is contraindicated in pregnancy, in active cancer, and in people whose pituitary axis has been disrupted by surgery, tumor, radiation or head injury. The tesamorelin side effects page has the full table.

Ipamorelin has no comparable safety table. In the 117-patient surgery trial, adverse events were common in both groups (87.5% on ipamorelin, 94.8% on placebo), and the authors described the drug as well tolerated over up to 7 days. Low potassium (12.5% versus 3.4%), insomnia (10.7% versus 5.2%) and high blood sugar at discharge (14.3% versus 8.6%) were more frequent on ipamorelin. Two people on ipamorelin died of complications after colon cancer surgery; FDA says it is unclear whether the deaths were related to the drug, and its safety-risk page cites “serious adverse events including death when ipamorelin was administered intravenously.” FDA also raises concern about immune reactions to injected peptide, and about the risks that come with any drug that raises growth hormone, including glucose intolerance and diabetes. Long-term effects of repeated injections under the skin have never been studied.

The asymmetry here is the point. One column comes from a label built on 806 people followed for 26 weeks or more. The other comes from 114 hospital patients given a different route of administration for a week.

Who each one suits

Tesamorelin fits a narrow group: adults with HIV and lipodystrophy who have excess visceral fat, under a prescriber who will monitor IGF-1 and blood sugar. Outside that group, any use is off-label, and the label itself rules out weight loss as a goal. It is also wrong for anyone pregnant, anyone with active cancer, and anyone whose pituitary has been affected by surgery, a tumor, radiation or head injury.

Ipamorelin fits no group on the evidence. FDA evaluated it for growth hormone deficiency and for slow bowel recovery after surgery, found no data supporting either by injection under the skin, and pointed to approved drugs for both: recombinant growth hormone for the first, alvimopan for the second. If growth hormone deficiency is the real question, the answer is testing, then an approved treatment if the test is positive.

What this comparison cannot tell you

• Which works better for muscle, fat or sleep. Neither has been tested for those. Tesamorelin’s trials measured visceral fat in one patient group, and ipamorelin’s measured bowel recovery.
• How they compare head to head. No trial has given both. Everything above comes from separate studies in different people, so the numbers cannot be lined up as a race.
• What ipamorelin does under the skin. That route has never been studied in people, which is also the route it is sold for.
• Whether a product contains what it claims. Tesamorelin from a pharmacy has an FDA-verified identity. A research-grade vial does not.

Which one a prescriber can use

Tesamorelin can be prescribed and dispensed through a licensed pharmacy, and its label sets out who should not use it. Ipamorelin cannot be lawfully prescribed as an approved drug or compounded under section 503A. Vials labeled “for research use only” fall under 21 CFR 312.160, which allows shipment only for laboratory animal or test-tube work, with a label reading “Not for use in humans.”

As of November 2, 2026, the HHS enforcement policy that lets pharmacies compound six named peptides without enforcement action does not include ipamorelin, so nothing in that announcement changes this page. For the other GHRH-based option, see sermorelin, and for the oral drug that uses ipamorelin’s receptor, see MK-677. The FDA status tracker keeps the dated record for all of them.